Sinobiopharma Announces Coverage By Harbinger Research

NANTONG CITY, China, July 8, 2010 (GLOBE NEWSWIRE) -- Sinobiopharma, Inc. ("Sinobiopharma" or the "Company"), (OTCBB:SNBP), an innovative biopharmaceutical products company with primary operations in China, today announced that Harbinger Research, LLC, an independent equity research firm, has initiated analyst research coverage on the Company.

Lisa Springer, CFA, Harbinger Research senior analyst, stated that, "Sinobiopharma is presently substantially undervalued compared to comparable companies and should benefit from significant future growth in the China pharmaceutical market for many years to come."

"We are very optimistic about the future growth of our company arising out of growing demand for improved healthcare services within China," said Dr. Lequn (Lee) Huang, Chairman and Chief Executive Officer. "Now is the best time to help Wall Street and the U.S. investment community truly understand the exceptional value that our company represents, as we enter into a period of rapid growth and expansion, driven by increasing demand for our market leading products."

Harbinger Research covers a number of U.S. listed China-based companies. To view Harbinger Research's initiation coverage on Sinobiopharma, please click on the following link, http://www.harbingerresearch.com/link/13/255/SNBP .

About Harbinger Research, LLC

Harbinger Research is an independent equity research firm that employs a research team consisting entirely of CFA charter holders and follows a number of companies across a wide variety of industries. Harbinger Research makes all of its reports available, free of charge, through its website at http://www.harbingerresearch.com and also distributes content through InvestorsInsight Publishing and most major financial portals.

About Sinobiopharma, Inc.

Sinobiopharma is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. Sinobiopharma has patented new methods for synthesizing active pharmaceutical ingredients (API) at a lower cost and owns drug delivery formulations that improve usability.For additional information, please visit the Company's website at: www.sinobp.com .

FORWARD LOOKING STATEMENTS